Real-World Evidence Prediction of a Phase IV Oncology Trial: Comparative Degarelix vs Leuprolide Safety.

Merola, David; Schneeweiss, Sebastian; Sreedhara, Sushama K; Zabotka, Luke E; Quinto, Kenneth; Concato, John; Wang, Shirley V

Merola, David; Schneeweiss, Sebastian; Sreedhara, Sushama K; Zabotka, Luke E; Quinto, Kenneth; Concato, John; Wang, Shirley V.

Afiliación

Merola D; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USAand.
Schneeweiss S; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Sreedhara SK; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USAand.
Zabotka LE; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Quinto K; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USAand.
Concato J; Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USAand.
Wang SV; Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

JNCI Cancer Spectr ; 2022 Aug 10.

Article en En | MEDLINE | ID: mdl-35947646

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: JNCI Cancer Spectr Año: 2022 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google